Search


USFDA draft guidance on : Cover Letter for Controlled Correspondences & ANDA Submissions
On December 10, 2021, the FDA published the draft guidance for industry entitled “Cover Letter Attachments for Controlled Correspondences...

Sharan Murugan
Dec 11, 20211 min read
Â
Â


Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making
Real-World Data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of...

Sharan Murugan
Dec 11, 20212 min read
Â
Â


Updated Version of Clinical Outcome Assessment Compendium -USFDA
The COA Compendium is part of the FDA’s efforts to foster patient-focused drug development. The COA Compendium is intended to facilitate...

Sharan Murugan
Dec 11, 20211 min read
Â
Â


Regulations & Requirements for Conducting Clinical Trials – SFDA
Saudi Food & Drug Authority released updated guidance on Regulations and Requirements for Conducting Clinical Trials in regards to “Early...

Sharan Murugan
Dec 7, 20211 min read
Â
Â


USFDA publishes FY 2022 GDUFA Science & Research Priority Initiatives & FY 2022 collaboration
On December 2,2021 the U.S. (FDA) published the Fiscal Year (FY) 2022 Generic Drug User Fee Amendments (GDUFA) Science and Research...

Sharan Murugan
Dec 5, 20211 min read
Â
Â


Guidance on QPPV including Pharmacovigilance System Master Files– MHRA
UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance on requesting a pharmacovigilance system master file...

Sharan Murugan
Dec 5, 20212 min read
Â
Â


Draft Guidance on Assessing Registries to Support Regulatory Decision -USFDAYesterday, the USFDA
Yesterday, the USFDA issued draft guidance for the industry titled Real-World Data: Assessing Registries to Support Regulatory...

Sharan Murugan
Nov 30, 20211 min read
Â
Â


MHRA’s updated Guidance on URGENT SAFETY MEASURE – UK
This guidance has been developed to assist those involved in clinical trials disrupted as a result of COVID-19. It is relevant to those...

Sharan Murugan
Nov 20, 20211 min read
Â
Â


Pharmaceutical Reference Standard – Guidance Update - SFDA
Standards and reference substances play a vital role in evaluating the quality of active pharmaceutical ingredients and finished...

Sharan Murugan
Nov 14, 20211 min read
Â
Â


Post-Authorisation Procedural Advice for Users of the Centralised Procedure – Updated guideline EMA
This guidance document addresses a number of questions that marketing authorisation holders (MAHs) may have on post-authorisation...

Sharan Murugan
Nov 14, 20211 min read
Â
Â


Knowledge aided Assessment and Structured Application (KASA) Initiative
The current challenges with the eCTD system that the agency currently uses, explaining how it does “not follow the development flow of...

Sharan Murugan
Nov 7, 20211 min read
Â
Â


Imports & Exports of Therapeutic Goods - Pakistan (DRAP)
Drug Regulatory Authority of Pakistan (DRAP) has released draft guidelines that describe the requirements for commercial imports and...

Sharan Murugan
Nov 7, 20211 min read
Â
Â


Guideline for Registration of Drug-Medical Device & Med.Dev-Drug Combo Products - MALAYSIA -NPRA
Drug-Medical Device Combination Product (DMDCP): Primary mode of action is based on pharmacological, immunological or metabolic action...

Sharan Murugan
Nov 7, 20211 min read
Â
Â


Data Standards for Drug & Biological Product Submissions Containing Real-World Data - USFDA
This guidance provides recommendations to sponsors for complying with section 745A(a) of the 30 FD&C Act (21 U.S.C. 379k-1(a)) when...

Sharan Murugan
Nov 7, 20211 min read
Â
Â


Updated Guideline on Registry-Based Studies (EMA)
This guideline addresses the methodological, regulatory and operational aspects involved in using registry-based studies to support...

Sharan Murugan
Nov 7, 20211 min read
Â
Â


Finland adopts New Act on Clinical Trials Legislation (FIMEA)
The Parliament of Finland has adopted a new Act on Clinical Trials on 8 October 2021. The Parliament also approved amendments to the...

Sharan Murugan
Nov 7, 20211 min read
Â
Â


Saudi Arabia’s (SFDA) Guide on Regulatory Framework for Drug Registration, Variation or Renewals
Saudi Arabia’s (SFDA) updated Guide on Regulatory Framework for Drug Registration, Variation or Renewal The Drug Sector in Saudi Food &...

Sharan Murugan
Oct 19, 20211 min read
Â
Â


South Africa’s (SAHPRA’s) updated Reliance Guideline for a New Registration or Variation Application
This guideline is intended to provide information and guidance to applicants/HCRs on the prescribed requirements and process to be...

Sharan Murugan
Oct 19, 20211 min read
Â
Â


UK-MHRA Guidance on Pharmacovigilance Procedures
This guidance summarises UK-MHRA’s approach to pharmacovigilance. The Guidance on pharmacovigilance procedures was Updated on 14 October...

Sharan Murugan
Oct 19, 20211 min read
Â
Â


ICH guideline Recommendation on Daily (PDE) Limits for Seven Mutagenic Impurities
The International Council for Harmonization (ICH) Endorsed on 6 October 2021 its (Addendum to M7(R2)) M7(R2) draft guideline setting new...

Sharan Murugan
Oct 12, 20211 min read
Â
Â
